ATR inhibitors (ATRi) mediate their anti-tumour activity by forcing tumour cells to enter into mitosis, subsequent to the impairment of the ATR-dependent surveillance of the G2/M cycle checkpoint. The gene discussed is ATR; the disease is neoplasm.